Equities

TFF Pharmaceuticals Inc

TFFP:NAQ

TFF Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.31
  • Today's Change0.00 / 0.00%
  • Shares traded53.99k
  • 1 Year change-72.46%
  • Beta1.3543
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.

  • Revenue in USD (TTM)1.20m
  • Net income in USD-19.39m
  • Incorporated2018
  • Employees19.00
  • Location
    TFF Pharmaceuticals Inc2600 Via Fortuna Ste 360AUSTIN 78746-7983United StatesUSA
  • Fax+1 (302) 655-5049
  • Websitehttps://tffpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Organovo Holdings Inc73.00k-13.99m7.63m12.00--1.07--104.48-1.39-1.390.00690.46350.006--0.74113,650.00-115.47-54.25-136.97-58.4250.68---19,160.27-1,890.163.38--0.00---70.54-48.7815.00---11.87--
Cyclerion Therapeutics Inc0.00-10.47m7.94m1.00--0.8393-----4.261.270.003.490.00----0.00-103.82-72.70-150.23-86.96-------2,565.62----0.00---100.00--30.98------
Intelligent Bio Solutions Inc3.11m-10.16m7.99m13.00--0.78--2.57-39.72-39.722.312.410.25791.928.60239,366.90-84.45-71.59-156.10-144.3645.81---327.50-565.481.42--0.0592--147.58596.394.47------
Pulmatrix Inc11.39m-10.84m8.00m22.00--0.6009--0.7021-2.97-2.973.123.640.483--21.64517,818.20-45.97-46.91-52.76-58.12-----95.18-238.04----0.00--20.21116.6225.03--104.29--
TFF Pharmaceuticals Inc1.20m-19.39m8.01m19.00--1.28--6.66-7.95-7.950.46591.810.1043--3.5163,293.68-168.10-79.57-212.66-83.41-----1,612.04-8,687.66----0.00--48.01--33.13------
Correlate Energy Corp5.65m-34.51m8.02m19.00------1.42-0.8359-0.83590.1457-0.04611.50--11.12297,377.40-915.61-315.47-----6.4515.42-610.79-201.03---1.07----122.2046.12-78.54------
Cell MedX Corp0.00-142.49k8.03m0.00---------0.0021-0.00210.00-0.00280.00-------190.76-703.78------84.03---2,996.54---4.35-----100.00--71.22------
Vitro Biopharma Inc2.11m-10.44m8.05m10.00------3.82-2.35-2.350.4745-1.690.27651.7120.61210,873.00-136.91---1,046.98--83.48---495.08--0.1865-4.19-----46.45--31.01------
Nascent Biotech Inc0.00-1.92m8.08m-----------0.012-0.0120.00-0.0030.00-------1,256.81-708.50-----------589.83------------25.47------
Mustang Bio Inc0.00-32.06m8.27m80.00---------2.91-2.910.00-0.23840.00----0.00-170.53-70.02-727.24-79.98--------------------33.44---60.75--
Silexion Therapeutics Corp0.00-523.87k8.50m0.00--1.33-----0.1403-0.14030.000.65590.00-------3.13---3.77--------------0.00-------54.96------
Carmell Corp12.32k-15.97m8.60m9.00------698.09-1.53-1.440.0006-0.0656------1,368.89--------58.73---129,263.60--0.6901-----------75.70------
ABVC Biopharma Inc136.40k-11.37m8.64m16.00--1.01--63.36-1.78-1.780.01720.68820.0114--0.42138,525.00-99.79-103.38-197.79-231.54-24.1176.25-8,762.13-2,019.89---2.500.1873---84.2885.3935.97------
Data as of Sep 20 2024. Currency figures normalised to TFF Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

18.47%Per cent of shares held by top holders
HolderShares% Held
Carlson Capital LPas of 30 Jun 2024293.46k8.47%
Armistice Capital LLCas of 30 Jun 2024185.70k5.36%
Westside Investment Management LLCas of 30 Jun 202450.49k1.46%
DRW Securities LLCas of 30 Jun 202440.00k1.15%
Geode Capital Management LLCas of 30 Jun 202421.80k0.63%
Renaissance Technologies LLCas of 30 Jun 202414.78k0.43%
The Vanguard Group, Inc.as of 30 Jun 202411.76k0.34%
NWAM LLCas of 30 Jun 202410.24k0.30%
BlackRock Fund Advisorsas of 30 Jun 20247.19k0.21%
Tower Research Capital LLCas of 30 Jun 20244.93k0.14%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.